Department of Medical Imaging and Radiology, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan.
Department of Nuclear Medicine, Cheng-Ching General Hospital, Chung-Kang Branch, Taichung, Taiwan.
J Nucl Cardiol. 2023 Dec;30(6):2454-2463. doi: 10.1007/s12350-023-03296-2. Epub 2023 May 31.
The present meta-analysis aims to investigate the effectiveness of heparin administration in suppressing physiological myocardial F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET)/computed tomography (CT), as its role in this regard has not been well investigated.
PRISMA guidelines were used to interrogate the PubMed, Embase, Cochrane library, Web of Knowledge, and www.clinicaltrail.gov databases from the earliest records to March 2023. The final analysis included five randomized controlled trials (RCTs). Meta-analysis was conducted to compare the effectiveness of unfractionated heparin (UFH) administration versus non-UFH administration, and subgroup analysis based on fixed and variable fasting durations was conducted. Effect sizes were pooled using a random-effects model, and the pooled odds ratios (ORs) were calculated.
Five eligible RCTs with a total of 910 patients (550 with heparin, 360 without heparin) were included. The forest plot analysis initially indicated no significant difference in the suppression of myocardial FDG uptake between the UFH and non-UFH groups (OR 2.279, 95% CI 0.593 to 8.755, p = 0.23), with a high degree of statistical heterogeneity (I = 91.16%). Further subgroup analysis showed that the fixed fasting duration group with UFH administration had statistically significant suppression of myocardial FDG uptake (OR 4.452, 95% CI 1.221 to 16.233, p = 0.024), while the varying fasting duration group did not show a significant effect.
According to the findings of our meta-analysis, we suggest that intravenous administration of UFH can be considered as a supplementary approach to suppress myocardial FDG uptake.
本荟萃分析旨在研究肝素给药在抑制正电子发射断层扫描(PET)/计算机断层扫描(CT)上生理心肌 F-氟脱氧葡萄糖(FDG)摄取方面的有效性,因为其在这方面的作用尚未得到充分研究。
使用 PRISMA 指南从最早的记录到 2023 年 3 月,对 PubMed、Embase、Cochrane 图书馆、Web of Knowledge 和 www.clinicaltrail.gov 数据库进行了查询。最终分析包括 5 项随机对照试验(RCT)。对给予普通肝素(UFH)与非 UFH 进行了比较,并进行了基于固定和可变禁食时间的亚组分析。使用随机效应模型对效应大小进行了汇总,并计算了汇总优势比(OR)。
纳入了 5 项符合条件的 RCT,共 910 例患者(550 例给予肝素,360 例未给予肝素)。森林图分析最初表明,UFH 组与非 UFH 组之间心肌 FDG 摄取的抑制作用无显著差异(OR 2.279,95%CI 0.593 至 8.755,p=0.23),且存在高度统计学异质性(I=91.16%)。进一步的亚组分析显示,固定禁食时间组给予 UFH 可显著抑制心肌 FDG 摄取(OR 4.452,95%CI 1.221 至 16.233,p=0.024),而可变禁食时间组则没有显著效果。
根据我们的荟萃分析结果,我们建议静脉给予 UFH 可作为抑制心肌 FDG 摄取的辅助方法。